Parkinson's Disease
June 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Parkinson's Disease abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Parkinson's Disease. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Parkinson's Disease. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Parkinson's Disease every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
Authors:Jellinger KA, Korczyn AD
Institution:Institute of Clinical Neurobiology, Alberichgasse 5/13, A-1150, Vienna, Austria. kurt.jellinger@univie.ac.at.
Journal:BMC Med. 2018 Mar 6;16(1):34. doi: 10.1186/s12916-018-1016-8.

2:Pharmacological interventions for psychosis in Parkinson's disease patients.
Authors:Friedman JH
Institution:a Movement Disorders Program , Butler Hospital , Providence , RI , USA. Providence , RI , USA.
Journal:Expert Opin Pharmacother. 2018 Apr;19(5):499-505. doi: 10.1080/14656566.2018.1445721. Epub 2018 Mar 1.

3:Effects of physical exercise programs on cognitive function in Parkinson's disease patients: A systematic review of randomized controlled trials of the last 10 years.
Authors:da Silva FC, Iop RDR, de Oliveira LC, Boll AM, de Alvarenga JGS, Gutierres Filho PJB, de Melo LMAB, Xavier AJ, da Silva R
Institution:University of State of Santa Catarina, Center for Health Sciences and Sports, Adapted Physical Activity Laboratory, Florianopolis, Santa Catarina, Brazil.; University of Brasilia, Faculty of Physical Education, Brasilia, Brazil.; University of Southern Santa Catarina, Medicine Course, Florianopolis, Santa Catarina, Brazil.
Journal:PLoS One. 2018 Feb 27;13(2):e0193113. doi: 10.1371/journal.pone.0193113. eCollection 2018.

4:The Risk of Traumatic Brain Injury Occurring Among Patients with Parkinson Disease: A 14-Year Population-Based Study.
Authors:Eric Nyam TT, Ho CH, Wang YL, Lim SW, Wang JJ, Chio CC, Kuo JR, Wang CC
Institution:Department of Neurosurgery, Chi Mei Medical Center, Tainan, Taiwan.; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan; Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.; Department of Rehabilitation, Chi Mei Medical Center, Tainan, Taiwan.; Department of Neurosurgery, Chi Mei Medical Center, Chiali, Tainan, Taiwan; Department of Nursing, Min-Hwei College of Health Care Management, Tainan, Taiwan.; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Journal:World Neurosurg. 2018 May;113:e328-e335. doi: 10.1016/j.wneu.2018.02.027. Epub 2018 Feb 13.

5:The potential role of herbal products in the treatment of Parkinson's disease.
Authors:Amro MS, Teoh SL, Norzana AG, Srijit D
Institution:Department of Anatomy, Universiti Kebangsaan Malaysia Medical Centre, 56000 Kuala Lumpur, Malaysia. Lumpur, Malaysia. Lumpur, Malaysia. Lumpur, Malaysia.
Journal:Clin Ter. 2018 Jan-Feb;169(1):e23-e33.

6:Cognitive impairment in Parkinson's disease, Alzheimer's dementia, and vascular dementia: the role of the clock-drawing test.
Authors:Allone C, Lo Buono V, Corallo F, Bonanno L, Palmeri R, Di Lorenzo G, Marra A, Bramanti P, Marino S
Institution:Department of Clinical Neurosciences and Neurobioimaging. Istituto di Ricovero e Cura a Carattere Scientifico, Centro Neurolesi 'Bonino-Pulejo' Messina, Messina, Italy.; Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
Journal:Psychogeriatrics. 2018 Mar;18(2):123-131. doi: 10.1111/psyg.12294. Epub 2018 Feb 7.

7:The launch of opicapone for Parkinson's disease: negatives versus positives.
Authors:Castro Caldas A, Teodoro T, Ferreira JJ
Institution:a Neurology Service, Department of Neurosciences , Hospital de Santa Maria , Lisbon , Portugal. Portugal. University Hospitals NHS Foundation Trust , London , United Kingdom.
Journal:Expert Opin Drug Saf. 2018 Mar;17(3):331-337. doi: 10.1080/14740338.2018.1433659.

8:Fatigue in Parkinson's disease: concepts and clinical approach.
Authors:Nassif DV, Pereira JS
Institution:Department of Neurology, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil. Rio de Janeiro, Rio de Janeiro, Brazil.
Journal:Psychogeriatrics. 2018 Mar;18(2):143-150. doi: 10.1111/psyg.12302. Epub 2018 Feb 6.

9:Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Authors:Svetel M, Tomic A, Kresojevic N, Kostic V
Institution:a Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine , University of Belgrade , Belgrade , Serbia.; b Clinic of Neurology , Clinical Center of Serbia , Belgrade , Serbia.
Journal:Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):353-360. doi: 10.1080/17425255.2018.1430138. Epub 2018 Jan 24.

10:Early occurrence of inspiratory muscle weakness in Parkinson's disease.
Authors:Baille G, Perez T, Devos D, Deken V, Defebvre L, Moreau C
Institution:Department of Neurology and Movement Disorders, Lille University Medical Center, Lille, France. Lille, France. France. Lille, France.
Journal:PLoS One. 2018 Jan 12;13(1):e0190400. doi: 10.1371/journal.pone.0190400. eCollection 2018.

11:Towards stem cell based therapies for Parkinson's disease.
Authors:Parmar M
Institution:Department of Experimental Medical Science, Wallenberg Neuroscience Center, Division of Neurobiology and Lund Stem Cell Center, Lund University, BMC A11, S-221 84 Lund, Sweden malin.parmar@med.lu.se.
Journal:Development. 2018 Jan 8;145(1). pii: 145/1/dev156117. doi: 10.1242/dev.156117.

12:Autophagy impairment in Parkinson's disease.
Authors:Karabiyik C, Lee MJ, Rubinsztein DC
Institution:Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, U.K. College of Medicine, Seoul 03080, Korea dcr1000@cam.ac.uk minjlee@snu.ac.kr. Cambridge Biomedical Campus, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, U.K. dcr1000@cam.ac.uk minjlee@snu.ac.kr. Campus, Hills Road, Cambridge, U.K.
Journal:Essays Biochem. 2017 Dec 12;61(6):711-720. doi: 10.1042/EBC20170023. Print 2017 Dec 12.

13:Predictors of Mortality in Nondemented Patients With Parkinson Disease: Motor Symptoms Versus Nonmotor Symptoms.
Authors:Santos-Garcia D, Suarez-Castro E, Ernandez J, Exposito-Ruiz I, Tunas-Gesto C, Aneiros-Diaz M, de Deus-Fonticoba T, Lopez-Fernandez M, Nunez-Arias D
Institution:1 Section of Neurology, Hospital Arquitecto Marcide/Hospital Naval, Complexo Hospitalario Universitario de Ferrol (CHUF), Ferrol, A Coruna, Spain.; 2 Department of Biochemistry and Molecular Biology, Boston University, Boston, MA, USA.; 3 Department of Psychiatry, Hospital Naval, Complexo Hospitalario Universitario de Ferrol (CHUF), Ferrol, A Coruna, Spain.
Journal:J Geriatr Psychiatry Neurol. 2018 Jan;31(1):19-26. doi: 10.1177/0891988717743589. Epub 2017 Nov 30.

14:Experiences of Persons With Parkinson's Disease Engaged in Group Therapeutic Singing.
Authors:Stegemoller EL, Hurt TR, O'Connor MC, Camp RD, Green CW, Pattee JC, Williams EK
Institution:Iowa State University.
Journal:J Music Ther. 2018 Jan 13;54(4):405-431. doi: 10.1093/jmt/thx012.

15:Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.
Authors:Barker RA, Parmar M, Studer L, Takahashi J
Institution:Department of Clinical Neuroscience and Cambridge Stem Cell Institute, Forvie Site, Cambridge CB2 0PY, UK. Lund Stem Cell Centre, Department of Experimental Medical Science, Lund University, 22184, Lund, Sweden. Electronic address: malin.parmar@med.lu.se. Cancer Center, New York, NY 10022, USA. Kyoto University, 606-8507, Kyoto, Japan.
Journal:Cell Stem Cell. 2017 Nov 2;21(5):569-573. doi: 10.1016/j.stem.2017.09.014.

16:Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial.
Authors:Bond AE, Shah BB, Huss DS, Dallapiazza RF, Warren A, Harrison MB, Sperling SA, Wang XQ, Gwinn R, Witt J, Ro S, Elias WJ
Institution:Department of Neurosurgery, University of Virginia Health Science Center, Charlottesville. Charlottesville. Charlottesville. Charlottesville. Charlottesville. Charlottesville. Charlottesville. Center, Charlottesville. Charlottesville.
Journal:JAMA Neurol. 2017 Dec 1;74(12):1412-1418. doi: 10.1001/jamaneurol.2017.3098.

17:Cognitive and Neuropsychiatric Features of Early Parkinson's Disease.
Authors:Getz SJ, Levin B
Institution:Department of Neurology, Division of Neuropsychology, University of Miami Miller School of Medicine, Miami, FL, USA. School of Medicine, Miami, FL, USA.
Journal:Arch Clin Neuropsychol. 2017 Nov 1;32(7):769-785. doi: 10.1093/arclin/acx091.

18:Some Clinically Useful Information that Neuropsychology Provides Patients, Carepartners, Neurologists, and Neurosurgeons About Deep Brain Stimulation for Parkinson's Disease.
Authors:Troster AI
Institution:Department of Clinical Neuropsychology and Center for Neuromodulation, Barrow Neurological Institute, Phoenix, AZ, USA.
Journal:Arch Clin Neuropsychol. 2017 Nov 1;32(7):810-828. doi: 10.1093/arclin/acx090.

19:Falls in Parkinson's disease: A complex and evolving picture.
Authors:Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L
Institution:Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada. Sydney, Australia. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. of Medicine, Tel Aviv University, Tel Aviv, Israel. University Medical Center, Chicago, Illinois, US. Newcastle upon Tyne, UK.
Journal:Mov Disord. 2017 Nov;32(11):1524-1536. doi: 10.1002/mds.27195. Epub 2017 Oct 25.

20:Successful Use of Escitalopram for the Treatment of Visual Hallucinations in Patients With Parkinson Disease.
Authors:Bergman J, Lerner PP, Sokolik S, Lerner V, Kreinin A, Miodownik C
Institution:*Mental Health Center, Ma'ale Carmel, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa; daggerGeha Mental Health Center, Petakh Tikva; double daggerIsrael Defense Force, Tel Aviv; and section signBe'er-Sheva Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
Journal:Clin Neuropharmacol. 2017 Nov/Dec;40(6):246-250. doi: 10.1097/WNF.0000000000000254.

21:A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
Authors:Herring WJ, Assaid C, Budd K, Vargo R, Mazenko RS, Lines C, Ellenbogen A, Verhagen Metman L
Institution:*Merck & Co, Inc, Kenilworth, NJ; daggerQUEST Research Institute, Bingham Farms, MI; and double daggerRush University Medical Center, Chicago, IL.
Journal:Clin Neuropharmacol. 2017 Nov/Dec;40(6):255-260. doi: 10.1097/WNF.0000000000000241.

22:Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.
Authors:Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, Baruch Y, Djaldetti R, Giladi N, Gurevich T
Institution:*Movement Disorders Unit, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv; daggerSackler School of Medicine, Tel Aviv University, Tel Aviv; double daggerTikun Olam, Research Department, Tel Aviv; section signSchool of Public Health, Epidemiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv; parallelOneWorld Cannabis Ltd, Petah-Tikva; paragraph signMovement Disorders Center, Rabin Medical Center, Petah-Tikva; and #Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Journal:Clin Neuropharmacol. 2017 Nov/Dec;40(6):268-272. doi: 10.1097/WNF.0000000000000246.

23:Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Authors:Sahli ZT, Tarazi FI
Institution:a Department of Psychiatry and Neuroscience Program , Harvard Medical School, McLean Hospital , Belmont , MA , USA. McLean Hospital , Belmont , MA , USA.
Journal:Expert Opin Drug Discov. 2018 Jan;13(1):103-110. doi: 10.1080/17460441.2018.1394838. Epub 2017 Oct 31.

24:Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds.
Authors:Zhang H, Bai L, He J, Zhong L, Duan X, Ouyang L, Zhu Y, Wang T, Zhang Y, Shi J
Institution:Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China. Electronic address: shijianyoude@126.com.; State Key Laboratory of Biotherapy & Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center of Biotherapy, Chengdu 610041, China. Electronic address: yiwenzhang@scu.edu.cn.
Journal:Eur J Med Chem. 2017 Dec 1;141:257-272. doi: 10.1016/j.ejmech.2017.09.068. Epub 2017 Sep 30.

25:Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
Authors:Francardo V, Schmitz Y, Sulzer D, Cenci MA
Institution:Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden. Electronic address: Veronica.Francardo@med.lu.se. Center: Division of Molecular Therapeutics, New York State Psychiatric Institute, New York 10032, NY, USA. Center: Division of Molecular Therapeutics, New York State Psychiatric Institute, New York 10032, NY, USA. Lund University, Lund, Sweden. Electronic address: Angela.Cenci_Nilsson@med.lu.se.
Journal:Exp Neurol. 2017 Dec;298(Pt B):137-147. doi: 10.1016/j.expneurol.2017.10.001. Epub 2017 Oct 5.

26:The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
Authors:Yabe I, Kitagawa M, Takahashi I, Matsushima M, Sasaki H
Institution:*Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University; and daggerDepartment of Neurology, Sapporo Teishinkai Hospital, Sapporo, Japan.
Journal:Clin Neuropharmacol. 2017 Nov/Dec;40(6):261-263. doi: 10.1097/WNF.0000000000000249.

27:Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?
Authors:Biundo R, Weis L, Fiorenzato E, Antonini A
Institution:Parkinson's Disease and Movement Disorders Unit, San Camillo Hospital IRCCS, Venice, Italy. Venice, Italy. Venice, Italy. Venice, Italy.
Journal:Arch Clin Neuropsychol. 2017 Nov 1;32(7):840-860. doi: 10.1093/arclin/acx092.

28:Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
Authors:Biundo R, Weis L, Abbruzzese G, Calandra-Buonaura G, Cortelli P, Jori MC, Lopiano L, Marconi R, Matinella A, Morgante F, Nicoletti A, Tamburini T, Tinazzi M, Zappia M, Vorovenci RJ, Antonini A
Institution:Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. Child Health, University of Genoa Genoa, Italy. Bologna, Bologna, Italy. Bologna, Italy.
Journal:Mov Disord. 2017 Nov;32(11):1557-1565. doi: 10.1002/mds.27181. Epub 2017 Sep 27.

29:Natural history of falls in an incident cohort of Parkinson's disease: early evolution, risk and protective features.
Authors:Lord S, Galna B, Yarnall AJ, Morris R, Coleman S, Burn D, Rochester L
Institution:Human Movement Science, Institute of Neuroscience, Newcastle University Institute for Aging, Newcastle University, Newcastle upon Tyne, NE4 5PL, UK. lynn.rochester@ncl.ac.uk.; NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK. lynn.rochester@ncl.ac.uk.; School of Clinical Sciences, Auckland University of Technology, Auckland, New Zealand.; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. lynn.rochester@ncl.ac.uk.; UK and Industrial Statistics Research Unit, Newcastle University, Newcastle upon Tyne, UK.
Journal:J Neurol. 2017 Nov;264(11):2268-2276. doi: 10.1007/s00415-017-8620-y. Epub 2017 Sep 25.

30:The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Authors:Lowin J, Sail K, Baj R, Jalundhwala YJ, Marshall TS, Konwea H, Chaudhuri KR
Institution:a QuintilesIMS , London , UK.
Journal:J Med Econ. 2017 Nov;20(11):1207-1215. doi: 10.1080/13696998.2017.1379411. Epub 2017 Sep 21.

31:More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota.
Authors:Mertsalmi TH, Aho VTE, Pereira PAB, Paulin L, Pekkonen E, Auvinen P, Scheperjans F
Institution:Department of Neurology, Helsinki University Hospital, Helsinki, Finland. Helsinki, Finland. Helsinki, Helsinki, Finland. Helsinki, Helsinki, Finland. Helsinki, Helsinki, Finland. Helsinki, Finland. Helsinki, Helsinki, Finland.
Journal:Eur J Neurol. 2017 Nov;24(11):1375-1383. doi: 10.1111/ene.13398. Epub 2017 Sep 11.

32:Glitazone use associated with reduced risk of Parkinson's disease.
Authors:Brakedal B, Flones I, Reiter SF, Torkildsen O, Dolle C, Assmus J, Haugarvoll K, Tzoulis C
Institution:Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Journal:Mov Disord. 2017 Nov;32(11):1594-1599. doi: 10.1002/mds.27128. Epub 2017 Sep 1.

33:Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Authors:Kianirad Y, Simuni T
Institution:a Department of Neurology , Northwestern University, Feinberg School of Medicine , Chicago , IL , USA. , Chicago , IL , USA.
Journal:Expert Rev Clin Pharmacol. 2017 Nov;10(11):1161-1168. doi: 10.1080/17512433.2017.1369405. Epub 2017 Oct 17.

34:Efficacy of Combined Treatment with Acupuncture and Bee Venom Acupuncture as an Adjunctive Treatment for Parkinson's Disease.
Authors:Cho SY, Lee YE, Doo KH, Lee JH, Jung WS, Moon SK, Park JM, Ko CN, Kim H, Rhee HY, Park HJ, Park SU
Institution:1 Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University , Seoul, Republic of Korea.; 2 Stroke and Neurological Disorders Center, Kyung Hee University Hospital at Gangdong , Seoul, Republic of Korea.; 3 Department of Epidemiology and Biostatistics, Graduate School of Public Health and Institute of Health and Environment, Seoul University , Seoul, Republic of Korea.; 4 Department of Neurology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University , Seoul, Republic of Korea.; 5 Integrative Parkinson's Disease Research Group, Acupuncture and Meridian Science Research Center, Kyung Hee University , Seoul, Republic of Korea.
Journal:J Altern Complement Med. 2018 Jan;24(1):25-32. doi: 10.1089/acm.2016.0250. Epub 2017 Jul 28.

35:Clinical approaches to the development of a neuroprotective therapy for PD.
Authors:Olanow CW, Kieburtz K, Katz R
Institution:Clintrex LLC, United States; Dept of Neurology, Dept of Neuroscience, Mount Sinai School of Medicine, New York, NY, United States. Electronic address: Warren.olanow@mssm.edu. States. States.
Journal:Exp Neurol. 2017 Dec;298(Pt B):246-251. doi: 10.1016/j.expneurol.2017.06.018. Epub 2017 Jun 13.

36:Management of lower urinary tract symptoms in Parkinson's disease in the neurology clinic.
Authors:Madan A, Ray S, Burdick D, Agarwal P
Institution:a College of Medical and Dental Sciences , University of Birmingham , Birmingham , UK. Kirkland , WA , USA. Kirkland , WA , USA. Kirkland , WA , USA.
Journal:Int J Neurosci. 2017 Dec;127(12):1136-1149. doi: 10.1080/00207454.2017.1327857. Epub 2017 May 25.

37:First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease.
Authors:Senek M, Hellstrom M, Albo J, Svenningsson P, Nyholm D
Institution:Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden.
Journal:Acta Neurol Scand. 2017 Dec;136(6):727-731. doi: 10.1111/ane.12756. Epub 2017 Mar 15.

For a FREE PREVIEW of the Medifocus Guidebook on Parkinson's Disease click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Parkinson's Disease click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Parkinson's Disease...
at a Special 20% Discount


Medifocus Guidebook on Parkinson's Disease

Updated: July 5, 2018
243 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Parkinson's Disease is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

PD73135996

Coupon Expires: September 14, 2018



What Our Customers Are Saying...

"I ordered the MediFocus Guidebook on Parkinson's Disease for my father who has had this condition for about 15 years. It was extremely useful to learn about the medications that are used to treat Parkinson's as well as the side-effects. I had read a lot of articles about Parkinson's on the Internet but they were all very general and vague. Your Guidebook provided excellent and comprehensive information from the medical perspective. Thanks for a very useful resource that is much needed today on the Web."
M.L.
Russelsheim, Germany


"I found your Guidebook on Parkinson's to be very informative for me, the patient, and for my husband. I am in the process of changing my medication and the book explained more to me than the doctor attempted to. I am now more aware of what to expect. It also offered valuable advice for the caregiver. Thank you."
M.N.
Palm Spring, California


"The Medifocus Guide to Parkinson's Disease was useful, informative, and allowed me to grasp the current fundamentals of treatment. I have recommended it to two of my ex-patients whom I know will find it readable and helpful to their needs."
G.B.
Research Triangle Park, NC



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.